Clinical Trial: Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional



Official Title: A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cells

Brief Summary:

Background:

Progressive Multifocal Leukoencephalopathy (PML) is a brain infection in people with a weakened immune system. Researchers think polyoma virus specific T cells (PyVST) therapy can treat PML. The PyVST cells are made from blood cells of a healthy relative. They are grown in a lab to expand the virus-killing cells, then given to the person with PML.

Objective:

To test whether PyVST safely treats PML.

Eligibility:

  • Adults ages 18 and older with PML

  • Healthy adults ages 18 and older who have:

    • Been screened under protocol 97-H-0041
    • A sibling, parent, or child with PML and matching cells

Design:

  • Participants will be screened with:

    • Medical history
    • Physical exam
    • Blood and urine tests

  • PML participants will also be screened with:

    • Cerebrospinal fluid removed by needle in the back.
    • MRI: A dye is injected in a vein. They lie on a table that slides into a cylinder.
    • Que